Pharma Mar (OTCMKTS:PHMMF) Short Interest Down 94.8% in July

Pharma Mar (OTCMKTS:PHMMF) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 13 shares, a decrease of 94.8% from the June 30th total of 252 shares. Based on an average daily trading volume, of 93 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company’s stock are short sold.

Analysts Set New Price Targets

A number of research analysts have weighed in on PHMMF shares. BTIG Research began coverage on shares of Pharma Mar in a research note on Thursday, April 23rd. They issued a “buy” rating on the stock. Zacks Research raised shares of Pharma Mar to a “hold” rating in a research report on Monday, June 15th. Finally, Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Pharma Mar Stock Performance

PHMMF stock remained flat at $86.09 during trading on Friday. Pharma Mar has a 12-month low of $77.41 and a 12-month high of $110.40. The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.14. The business has a fifty day moving average of $91.98 and a 200-day moving average of $93.84.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.